Aclaris Therapeutics (ACRS) Common Equity (2014 - 2026)

Aclaris Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $143.6 million for Q1 2026.

• On a quarterly basis, Common Equity changed 0.29% year-over-year to $143.6 million in Q1 2026; TTM through Mar 2026 was $143.6 million, a 0.29% change from a year earlier, with the FY2025 full-year figure at $103.1 million, down 33.73% from the prior year.
• Common Equity climbed to $143.6 million in Q1 2026 per ACRS's latest filing, from $103.1 million in the prior quarter.
• Across five years, Common Equity topped out at $235.8 million in Q2 2022 and bottomed at $103.1 million in Q4 2025.
• The 5-year median for Common Equity is $155.6 million (2024), against an average of $159.3 million.
• Across the five-year window, Common Equity surged 60.47% in 2022 and sank 33.73% in 2025, its largest moves.
• Year by year, Common Equity stood at $197.6 million in 2022, then dropped by 20.46% to $157.2 million in 2023, then retreated by 1.03% to $155.6 million in 2024, then plunged by 33.73% to $103.1 million in 2025, then soared by 39.35% to $143.6 million in 2026.
• Per Business Quant, the three latest ACRS Common Equity figures stand at $143.6 million (Q1 2026), $103.1 million (Q4 2025), and $120.1 million (Q3 2025).